Background: It is well known that the tumor microenvironment (TME) has been received an increasing number of attention. CXC chemokines could regulate immune cell transport and tumor cell activity, thus exerting anti-tumor immunity. However, studies on the expression and prognosis of CXC chemokines in cervical cancer (CC) are more limited. Methods: The study investigated the role of CXC chemokines in the TME and prognosis of CC using public databases. Moreover, quantitative real-time PCR (Q-PCR) and immunohistochemistry (IHC) of CXC chemokines were performed to further verify. Results: The transcriptional levels of CXCL1/3/5/6/8/9/10/11/13/14/16/17 in CC tissues were significantly elevated while the transcriptional levels of CXCL2/4/7/12 were significantly reduced. We reached a consistent conclusion that the expression of CXCL9/10/11/13 was verified by Q-PCR and IHC. Moreover, CC patients with low transcriptional levels of CXCL1/2/3/4/5/8 were signifi-cantly associated with longer overall survival (OS). Our data suggest that RELA, NFKB1, and SP1 are key transcription factors for CXC chemokines, and the LCK, LYN and PAK are CXC chemokine kinases targets. We found significant correlations among the expression of CXC chemokines and the infiltration of six types of immune cells. Conclusions: We performed a comprehensive analysis of CXC chemokines via clinical data and some online tumor database. Our results may provide new idea for the selection of immunotherapeutic targets and prognostic biomarkers for cervical cancer.

Background: ELL-associated factor 2 (EAF2) plays an important role in transcription elongation and the regulation of gene expression in both mammalian cells as well as in lower eukaryotes concurrent . EAF2’s depletion has been demonstrated to enhance cell proliferation and greatly increase the risk of cancer. However, little is known about the expression and function of EAF2 in cervical cancer (CC) progression. Here, we comprehensively analyzed the expression of EAF2 and its clinical outcome in CC using publicly available cancer gene expression and patient survival data through various databases.Methods: We examined the differences of EAF2 expression between cancers and their normal tissues using the Oncomine, Gene expression Profiling Interactive Analysis 2 (GEPIA2), the Gene Expression across Normal and Tumor tissue 2 (GENT2) database and UALCAN databases. EAF2 expression was investigated from immunohistochemistry images using the Human Protein Atlas database. Copy number alterations (CNAs) and mutations of EAF2 were analyzed using cBioPortal. Kaplan–Meier analysis was used to predict the survival of EAF2 in CC. Analysis of the co-expression profile of EAF2 and the enrichment pathway of co-expression with EAF2 were revealed using LinkedOmics to explore the predicted signaling pathways. GeneMANIA visualize the gene networks and predict function of genes that GSEA identified as being enriched in CC: kinase LYN, mi-RNA133A, 133B and transcription factor OCT1. Results: We found that the expression of EAF2 decreased with the development of CC and significant upregulation of EAF2 is positively correlated with the overall survival (OS) of CC patients. The decrease of EAF2 gene expression may be partly due to promoter methylation and CNAs with the development of CC. Besides, EAF2 expression might be strongly positively correlated with the expression of IQCB1, ILDR1 and ASTE1, and may contribute to a signaling pathway in CC. Conclusion: Decreased EAF2 expression has negative clinical significance in the development of CC through the regulation of methylation, CNAs and related pathways. This suggests that EAF2 has potential as a therapeutic target for CC. Keywords: EAF2; cervical cancer; patient survival; clinical outcomes; cancer progression; multiomics analysis